Designs for phase II trials with trade-of between efficacy and toxicity

MaRDI QIDQ3511752zbMATH OpenFDO

Authors Menggan Yu, Constantin T. Yiannoutsos

Publication date 11 July 2008

zbMATH Keywords

tablestwo-stage designbivariate outcome

Mathematics Subject Classification ID

Parametric hypothesis testing (62F03) Applications of statistics to biology and medical sciences; meta analysis (62P10) Sequential statistical design (62L05)

Recommendations

• Incorporating Toxicity Considerations Into the Design of Two-Stage Phase II Clinical Trials
• Treatment Comparisons Based on Two‐Dimensional Safety and Efficacy Alternatives in Oncology Trials
• On construction of single-arm two-stage designs with consideration of both response and toxicity
• Dose-Finding Based on Efficacy-Toxicity Trade-Offs
• Efficient designs for phase II oncology trials with ordinal outcome

Cited in

(9)

• Phase 2 and 3 Combination Designs to Accelerate Drug Development
• Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
• A hybrid geometric phase II/III clinical trial design based on treatment failure time and toxicity
• Treatment Comparisons Based on Two‐Dimensional Safety and Efficacy Alternatives in Oncology Trials
• Efficient designs for phase II oncology trials with ordinal outcome
• Optimal designs for active controlled dose-finding trials with efficacy-toxicity outcomes
• Two-stage phase II trials with early stopping for effectiveness and safety as well as ineffectiveness or harm
• Incorporating Toxicity Considerations Into the Design of Two-Stage Phase II Clinical Trials
• On construction of single-arm two-stage designs with consideration of both response and toxicity

This page was built for publication: Designs for phase II trials with trade-of between efficacy and toxicity

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3511752)